<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660933</url>
  </required_header>
  <id_info>
    <org_study_id>POSTPARTFEEV</org_study_id>
    <nct_id>NCT00660933</nct_id>
  </id_info>
  <brief_title>Intravenous Iron Versus Oral Iron for Severe Postpartum Anemia</brief_title>
  <official_title>Intravenous Iron Versus Oral Iron for Severe Postpartum Anemia Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare the effect of intravenous versus oral iron in women with
      severe postpartum anemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postpartum anemia is commonly defined as hemoglobin levels less than 8.5 g/dl and it is
      usually treated with oral iron supplements. Blood transfusion is reserved to women with
      hemoglobin levels &lt; 6 g/dl and/or clinical symptoms of anemia. Without treatment, the
      restoration of blood parameters in postpartum anemia can take approximately one month
      (hemoglobin levels increase to 2.8 g/dl in 30 days). Several reports have demonstrated the
      efficacy of intravenous iron in severe anemia in non-obstetric pathologies. However, the
      clinical effect of intravenous iron in patients with postpartum hemoglobin levels ranging
      from 6.0 to 8.0 g/dl has been not reported. There has not been evaluated its capacity to
      restore hemoglobin levels and to minimize clinical side-effects of anemia (sickness,
      weariness, depression, anxiety).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate if intravenous iron administration is better than oral treatment to improve hemoglobin and hematocrit parameters in women with severe postpartum anemia</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare if the administration of intravenous iron supplementation is better than the oral dosage to reestablish clinical symptoms of severe anemia minimizing its side-effects (weariness, depression, anxiety) or to avoid the need for blood transfusion</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Anemia</condition>
  <condition>Puerperal Disorders</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A: Administration of intravenous iron sucrose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B: Administration of intravenous NaCl 0,9%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron sucrose</intervention_name>
    <description>Iron sucrose 200 mg/day iv, (20 mg/ml) + 200 cc de NaCl 0,9%/day in 60 minutes per 2 days.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Venofer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl</intervention_name>
    <description>NaCl 0,9% 200 ml /day iv in 60 minutes per 2 days</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years and older,

          2. Diagnosis of postpartum anemia within the first 48 h postpartum with an haemoglobin
             level equal or higher than 6 g/dL and lower than 8.0 g/dL,

          3. Ability to read and understand the relevant purpose of the trial and consent obtained
             in accordance with specifications of the local research ethics committee.

        Exclusion Criteria:

          1. Clinical symptoms or suspicion of acute or chronic infection.

          2. Allergic history or iron intolerance.

          3. Indication of blood transfusion.

          4. Non iron deficit anemia.

          5. Hepatopathy.

          6. Parenteral iron hypersensitivity.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Montse Palacio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servei de Medicina Maternofetal. Institut de Ginecologia, Obstetrícia i Neonatología. Hospital Clínic. Universitat de Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Perelló MF, Coloma JL, Masoller N, Esteve J, Palacio M. Intravenous ferrous sucrose versus placebo in addition to oral iron therapy for the treatment of severe postpartum anaemia: a randomised controlled trial. BJOG. 2014 May;121(6):706-13. doi: 10.1111/1471-0528.12480. Epub 2014 Jan 15.</citation>
    <PMID>24423186</PMID>
  </reference>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2008</study_first_submitted>
  <study_first_submitted_qc>April 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <name_title>Montse Palacio</name_title>
    <organization>Hospital Clínic of Barcelona</organization>
  </responsible_party>
  <keyword>postpartum anemia</keyword>
  <keyword>intravenous iron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Puerperal Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric oxide, saccharated</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 19, 2016</submitted>
    <returned>October 11, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

